Shire Pharmaceuticals ( SHPGY) fell 26% in Instinet premarket trading after warning that competitive pressure may dampen growth in 2002.

The British specialty drugmaker faces stiff competition from generic versions of Adderall, Shire's top-selling hyperactivity drug. Additionally, new marketing expenses are expected to impact the company's results.

Shares of Shire were recently trading at $24 after closing yesterday at $32.45.

If you liked this article you might like

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Tough Month, Better Quarter for Retailers

Tough Month, Better Quarter for Retailers

AON Plunges on Accounting Issues, Earnings

AON Plunges on Accounting Issues, Earnings

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Polo Posts Lower First-Quarter Results

Polo Posts Lower First-Quarter Results